Combined liver-kidney transplantation in patients with complicate end stage of liver-kidney disease:one case report

彭志海,祝哲诚,徐达,夏强,裘正军,李克
DOI: https://doi.org/10.3969/j.issn.1672-8467.2002.02.016
2002-01-01
Abstract:Purpose: To invesagate the surgical techniques, clinical experiences and therapeutic effects of combined liver-kidney transplantation(CLKT). Methods: Combined liver-kidney transplantaûon was performed on one patient with liver, cirrhosis and hepatic enoephalopathy of hepatitis B and uremia of chronic nephritis complicated with milticapsular liver, bilateral kidney and portal vein stenosis. ABO blood type incompatible but matched (group O-to-B) cadavetic allografts were used in the CLKT. Liver and kidney transplantation was carried out by using orthotopic and ordinary methods respectively. The humanized mAb Daclizumab(Zenapax) was given to recipient as immuned induction treatment at preoperative one hour and postoperative 14 days respectively. Baseline immunosuppressive drugs consisted of FK506, mycophenolate mofetil(MMF) and corticosteroid. Lamividine was used on day 60 preoperation and day 7 postoperation respectively. In the meantime hepatitis B immunoglobin (HBIg) was injected musclely. Results: The complications included acute and chronic rejection has not been taken placed sinoe the transplantation day. Both transplant organs had rapidly normal functions postoperation, without primary nonfunction of liver graft happened. The patients has been survived for 10 months with normal life quality. Conclusions: Skilled operation techniques, comprehensive monitoring perioperatively and correct management are all major factors for success. ABO blood type incompatible but matched(group O-to-B) cadaveric CLKT can be performed safely. The induction treatment of Zenapax and baseline immunosuppression consisted of FK506, MMF and cortiocosteroid are effective and safe. Combination therapies of Lamividine and HBIg to prevent HBV recurrence may be more effective.
What problem does this paper attempt to address?